Disclaimer
The contents of this article are the personal views of the authors and are not intended to represent the official views of institutions with which the authors are affiliated, or the National Institutes of Health or the National Institute of Allergy and Infectious Diseases.
Financial & competing interests disclosure
This work was supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health through contracts U01AI061142 and HHSN272200800039C. Nikolai Petrovsky is on the management team of Vaxine, a company developing new influenza vaccine adjuvant technologies. Dimitar Sajkov has been a principal investigator for vaccine clinical trials sponsored by Vaxine. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.